ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis

• Status: Completed
• Trial end date: 2018-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the incidences of GVHD and viral infections in haploidentical hematopoietic stem cell transplant recipients receiving different dose of antithymocyte globulin (ATG) for acute graft-versus-host disease(aGVHD) prophylaxis. Our first objective was to investigate the optimal dose of ATG for aGVHD and second object was to evaluate the effect of different dose of ATG on post-transplant viral infection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanfang Hospital of Southern Medical University
• Collaborators: First Affiliated Hospital of Guangxi Medical University; Fujian Medical University Union Hospital; Guangxi Medical University; Guangzhou General Hospital of Guangzhou Military Command; Peking University People's Hospital; Southern Medical University, China; Xiangya Hospital

Criteria

Inclusion Criteria:

• A patient age of 14-65 years

• Haploidentical hematopoietic stem cell transplant recipient

• Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study

Exclusion Criteria:

• Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)

• Patients with any conditions not suitable for the trial (investigators' decision)